intrahepatic cholangiocarcinoma. British Journal of Cancer 2019 (120), 
      165-171. ClinicalTrials.gov identifier: NCT01752920 
 
  11. FIDES-02: ClinicalTrials.gov identifier: NCT04045613 
 
  12. FIDES-03: ClinicalTrials.gov identifier: NCT04604132 
 
  13. S. K. Saha, A. X. Zhu, C. S. Fuchs et al. Forty-year trends in 
      cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the 
      rise. The Oncologist 2016 (21), 594-599 
 
  14. A. Lamarca, D. H. Palmer, H. S. Wasa et al. Second-line FOLFOX 
      chemotherapy versus active symptom control for advanced biliary tract 
      cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. 
      Lancet Oncology 2021 (22):690-701

Attachment 


   --  Press release (PDF) 
      https://ml-eu.globenewswire.com/Resource/Download/6cfefbd0-3ae9-4e92-886b-278e5e5f73f9

(END) Dow Jones Newswires

September 17, 2021 01:15 ET (05:15 GMT)